<table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5 Cumulative Rates of Genotypic Resistance to Tyzeka through Week 208</caption>
<col width="200"></col>
<col width="120"></col>
<col width="250"></col>
<col width="250"></col>
<tbody>
<tr>
<td align="center" colspan="2" rowspan="2" stylecode="Lrule Rrule ">Trial</td>
<td align="center" colspan="2" stylecode="Toprule Lrule Rrule ">Cumulative genotypic resistance rate<sup>1</sup>
</td>
</tr>
<tr>
<td align="center" stylecode="Toprule Lrule Rrule ">Overall study population</td>
<td align="center" stylecode="Toprule Lrule Rrule ">Subjects treated with Tyzeka according to current dosing recommendations<sup>2</sup>
</td>
</tr>
<tr>
<td align="center" rowspan="2" stylecode="Toprule Lrule Rrule ">NV-02B-007<br/>(007 GLOBE trial)</td>
<td align="center" stylecode="Toprule Lrule Rrule ">Week 52</td>
<td align="center" stylecode="Toprule Lrule Rrule ">7%</td>
<td align="center" stylecode="Toprule Lrule Rrule ">0%</td>
</tr>
<tr>
<td align="center" stylecode="Toprule Lrule Rrule ">Week 104</td>
<td align="center" stylecode="Toprule Lrule Rrule ">22%</td>
<td align="center" stylecode="Toprule Lrule Rrule ">3%</td>
</tr>
<tr>
<td align="center" rowspan="2" stylecode="Toprule Botrule Lrule Rrule ">CLDT600A2303<br/>(104-week extension trial)</td>
<td align="center" stylecode="Toprule Lrule Rrule ">Week 156</td>
<td align="center" stylecode="Toprule Lrule Rrule ">30%</td>
<td align="center" stylecode="Toprule Lrule Rrule ">12%</td>
</tr>
<tr>
<td align="center" stylecode="Toprule Lrule Rrule ">Week 208</td>
<td align="center" stylecode="Toprule Lrule Rrule ">35%</td>
<td align="center" stylecode="Toprule Lrule Rrule ">16%</td>
</tr>
<tr>
<td colspan="4" stylecode="Toprule ">
<sup>1</sup>The cumulative rates of genotypic resistance to Tyzeka were calculated using the formula previously described by Pawlotsky et al. (2008).</td>
</tr>
<tr>
<td colspan="4">
<sup>2</sup>Tyzeka dosing recommendations are provided in this Package Insert [<content stylecode="italics">see Indications and Usage (1.1) and Dosage and Administration (2.1)</content>].</td>
</tr>
</tbody>
</table>